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detected in 36, 47, and 17% of pts and 34, 47, and 19% of donors,
respectively. G2677T polymorphism included GG, GT and TT
genotypes that were detected in 29, 55, and 16% of pts and 34, 49,
and 17% of donors, respectively. The cumulative incidence of
acute GVHD grade III-IV was 38% (24-62), 18% (9-35) and 18%
(6-50), when the donors had CC, CT and TT in the C3435T site,
respectively (p0.02). Multivariable analysis determined donor
CC (HR 2.4, p0.05) and alloSCT from female to male (HR 5.1,
p0.03) as the most signiﬁcant factors predicting for severe acute
GVHD while donor, disease and conditioning type were not sig-
niﬁcant. The overall incidence of grade II-IV GVHD was not
statistically different between the genotypes. Pt C3435T polymor-
phism and pt or donor G2677T polymorphisms had no correlation
with GVHD. The cumulative incidence of chronic GVHD was
84% (95%CI, 68-100), 53% (38-75) and 38% (39-63) when the
donors had CC, CT and TT in the C3435T site, respectively
(p0.02). Multivariable analysis determined donor CC (HR 2.2,
p0.01), alloSCT from female to male (HR 2.5, p0.03) and
unrelated donor (HR 1.8, p0.05) as the most signiﬁcant factors
predicting for chronic GVHD. The CC genotype in C3435T is
known to be associated with higher expression level of P-glycop-
rotein (Pgp). We speculate that increased Pgp may result in lower
intracellular levels of cyclosporine in donor T-cells leading to
higher incidence of GVHD. Furthermore, Pgp may be involved in
transporting cytokines that are critical to the pathogenesis GVHD.
Further studies will be required to determine the mechanism of the
association of C3435T polymorphism, Pgp expression and
GVHD. In conclusion, C3435T polymorphism in the MDR1 gene
may be an important factor in predicting GVHD and may be
considered when selecting the most suitable donor.
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INFLUENCE OF KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR)
MATCHING ON THE DEVELOPMENT OF CHRONIC GRAFT-VS.-HOST
DISEASE (CGVHD) IN T-CELL DEPLETED MATCHED UNRELATED DO-
NOR (MUD) ALLOGENEIC BONE MARROW TRANSPLANTATION (AL-
LOBMT)
Sobecks, R.1, Askar, M.1, Ball, E.2, Rybicki, L.1, Thomas, D.1,
Bates, J.1, Kalaycio, M.1, Andresen, S.1, Pohlman, B.1, Dean, R.1,
Sweetenham, J.1, Maciejewski, J.1, Bolwell, B.1 1The Cleveland Clinic,
Cleveland, OH; 2London Health Sciences Centre, London, ON, Canada.
The reactivity of NK cells and some T cell populations is regu-
lated by KIR interactions with HLA class I molecules. Such inter-
actions have been suggested to inﬂuence outcomes after alloBMT.
However, the effect of KIR interactions on the development of
cGVHD after MUD alloBMT has not been well described. We
analyzed 30 pts who received a 12/12 HLA MUD T-cell depleted
myeloablative alloBMT at our institution from 5/5/95-2/6/04.
Diagnoses included 17 AML, 6 ALL, 4 CML and 3 MDS. GVHD
prophylaxis consisted of Tacrolimus and methotrexate (5 mg/m2
days 1, 3, 6 and 11). The median age was 40 (range, 19-58). KIR
genotypes were determined for donors by PCR-RSSOP analysis.
Recipient HLA KIR ligands were categorized as: 1) HLA-Cw
groups C1 ( or -); 2) C2 ( or -); 3) HLA-Bw4 ( or -); and 4)
HLA-A3 or -A11 ( or -) [as reviewed by Farag et al. Blood 2002;
100:1935-47]. Donor KIR genotype and recipient HLA KIR li-
gands were used to generate an inhibitory KIR score for pts from
1 to 4 corresponding to the potential number of donor inhibitory
KIRs engaged with recipient HLA KIR ligands. Eight pts had a
score of 1, 11 had a score of 2, 9 had a score of 3 and 2 had a score
of 4. The Kaplan-Meier method was used to estimate the achieve-
ment of cGVHD by inhibitory KIR score. Pts with a score of 1-2
compared to those with a score of 3-4 were more likely at 6 mos to
develop cGvHD (71% vs. 0%, respectively, p0.002)and extensive
cGvHD (48% vs. 0%, respectively, p0.06). Only 1 (9%) pt with
a score of 3-4 developed cGvHD (limited stage) at 29.9 mos while
7 (37%) with a score of 1-2 developed cGvHD (4 extensive stage)
at a median of 3.8 mos (range, 3.3-7.6). No differences were found
between these 2 groups regarding the development of grade 2-4 or
grade 3-4 acute GVHD or with regards to age, race, sex, number
of prior chemotherapies, disease status at BMT, preparative regi-
men, total nucleated and CD34 cell doses. Pts with lower inhib-
itory KIR scores may have more active anti-recipient, donor-
derived effector cells (NK cells and T cell subsets) that may result
in increased cGVHD. Conversely, those with higher inhibitory
KIR scores may have less active populations and be less likely to
develop cGVHD. Given the genotypic potential to inhibit all NK
cells KIR expression may be variable among different clones, and
may affect the development of cGVHD. Further investigation of
KIR expression at the cellular level rather than by genotyping
alone should be pursued.
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CHANGES IN LYMPHOCYTES AND REGULATORY T CELLS IN CHRONIC
GVHD
Tabellini, L.1, Haeusermann, P.1, Flower, M.E.1, Grogan, B.M.1,
Bumgarner, T.E.1, Damodaran, A.C.1, Martin, P.J.1, Hansen, J.A.1
1Fred Hutchinson Cancer Research Center, Seattle, WA.
Regulatory T cells (Treg) are believed to play an important role
in modulating the severity of GVHD and the development of
immunological tolerance after HCT. Studies reported here were
undertaken to determine in more detail the presence and activity of
Treg and interactions with other pathways known to affect regu-
latory function.
Ninety patients were enrolled between 6 and 198 months (me-
dian 19) post-HCT including 6 patients with no prior acute or
chronic GVHD, 64 with prior aGVHD, 72 who developed exten-
sive cGVHD and 18 who had been withdrawn from all immune
suppression therapies (IST). These 90 patients were classiﬁed ac-
cording to current GVHD status and IST: group A, active/un-
treated extensive cGVHD; group B, active cGVHD on high dose
IST; group C, quiescent cGVHD on low IST; group D, tolerant
patients off IST. PBMC were isolated for immunophenotype and
gene expression studies.
Number of CD4 T cells and CD4:CD8 ratio were lower in all
groups compared to controls (p0.02 and 0.03). HLA-DR was
increased in all patients (p0.000) ranging from 14% to 20% of
CD4 and from 34% to 41% of CD8.
The %CD4CD25CD127lo Treg cells in PBL in tolerant was
higher (9.33%) compared to active and quiescent patients (5.9%
and 6.3% respectively, p0.05) and to controls (7.2%, pns).
Gene expression in PBMC was evaluated by real time PCR for
IFNG, IL2RA, IL7R IL10, TGFB and FOXP3. IFNG was in-
creased in active patients compared to controls (p0.02), it tended
to be lower than controls in quiescent and similar to controls in
tolerant patients. IFNG in patients overall correlated with the
%CD8DR (p0.04). IL10 expression was increased in all pa-
tients compared to controls (p0.02) with the highest levels in
quiescent cGVHD. IL10 was lower in tolerant but remained
higher than controls (p0.02). TGFB expression was increased
only in patients with active disease on high dose IST (p0.05).
IL7R was decreased in all patients (p0.000).
FOXP3 expression was signiﬁcantly lower in active and quiescent
cGVHD (p0.02) compared to controls. Average FOXP3 in tol-
erant was similar to controls, however the range for tolerant was
skewed towards below normal levels.
These studies support the theory that FOXP3 plays an important
role in induction of tolerance, but they also suggest a signiﬁcant
role for other immune regulator molecules including TGFB and
IL10. Additional studies will be necessary to more clearly deﬁne
molecular and functional interactions between these regulatory
factors.
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VB TCR USAGE AND TREG CD4CD25CTLA4/- CELLS IN ACUTE
AND CHRONIC GRAFT VERSUS HOST DISEASE, (GVHD), PATIENTS
SUBMITTED TO EXTRACORPOREALPHOTOTHERAPY, (ECP): A STUDY
TO EVALUATE THEIR PREDICTIVE SIGNIFICANCE ON THE GVHD OUT-
COME
Tassi, C.1, Arpinati, M.2, Tazzari, P.L.1, Ricci, F.1, Conte, R.1 1Servi-
zio Medicina Trasfusionale-Policlinico Sant’Orsola, Bologna, Italy; 2Is-
tituto Di Ematologia Ed Oncologia Seragnoli-Policlinico Sant’Orsola,
Bologna, Italy.
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ECP is largely used in Acute and Chronic GVHD patients.
Moreover, some multicenter studies are ongoing to evaluate future
ECP employment in GVHD prevention. Therefore, laboratory
and clinical parameters predictive of ECP response would be ex-
tremely useful. For istance, recent published data shown great
interest on VBTCR oligoclonal CD4 or CD8 subsets, and T reg
CD4CD25 CTLA 4/-, which could be used as predictive
factors for GVHD outcome.
We present data from seriate, cytoﬂuorimetry phenotype studies
performed on 200 blood samples from 4 aGVHD and 13 cGVHD
patients that underwent ECP in our Apheresis Unit.
15/17 had skin involvement oral mucose and/or ocular disease,
3/17 showed liver GVHD, 2/17 had lung function compromised.
Schedule for ECP therapy established 6 and 12 months of treat-
ment for Acute or Chronic GVHD, respectively.Clinical evalua-
tion was made every three months and according to known pro-
tocols.Skin and oral mucosa improvement was achieved in the 64%
of the patients, liver recovery was stabilized in the 30%, while no
response was reported in lung function.
Finally, after more than 6 months of treatment, 3/14 cGVHD
patients failed to respond and 3/14 maintained stable disease with-
out steroids administration.
A pathological increment of the VBTCR CD4 or CD8 oli-
goclones (being ﬁxed as 15% of the circulating lymphocytes) was
found in 10/17 patients. VB20, VB16, VB14 and VB3 were the
most recurrent oligoclones, but we could ﬁnd only weak correla-
tions with ECP response-rate, kind and extension of GVHD. At
the start of ECP, Treg CD4CD25CTLA4 (mean 0.4% of
the circulating CD4) were detected in all 2 cGVHD and in 1
aGVHD early responders to ECP. This subset was lacking in 3
ECP refractory patients in which, on the contrary, was detectable
the subset CD4CD25CTLA4- (mean 1.6% of the circulating
CD4) also detectable in the other 11 remaining patients. Inter-
estingly, in this last group of subjects Treg cells seemed to be
correlated to the ECP response rate. In particular, responders
showed inverse trends in the CTLA4 (increasing) or CTLA4-
(decreasing) subsets during ECP treatment.
In conclusion, Treg subpopulations seem to be useful as predic-
tive factors of GVHD outcome, in accordance with other studies
results. Nevertheless, further research is still necessary in order to
draw deﬁnitive conclusions.
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CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE
1 IS AN IMPORTANT SUPPRESSOR OF INTESTINAL AND SYSTEMIC
ACUTE GRAFT-VERSUS-HOST-DISEASE
van den Brink, M.R.M.1, Willis, L.1, Bautista, J.1, Chow, M.1,
Smith, O.M.1, Cabrera-Perez, J.1, Suh, D.1, King, C.1,
Zakrzewski, J.1, Kochman, A.1, Hubbard, V.1, Turbide, C.2,
Beauchemin, N.2, Lu, S.X.1 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2McGill University, Montreal, QC, Canada.
Carcinoembryonic antigen related cell adhesion molecule 1
(CEACAM-1) is a transmembrane glycoprotein found on leukco-
cytes, endothelium, and epithelium, and its activation can attenu-
tate colitis in murine models. Microarray analysis revealed that
CEACAM-1 expression is increased during gut graft-versus-host-
disease (GVHD). We studied the role of CEACAM-1 in a mouse
allogeneic bone marrow transplantation model (B63BALB/c]).
Using CEACAM-1-/- mice as recipients or T cell donors caused
sigiﬁcantly worse GVHD (p0.05) compared to wildtype (WT)
controls.
Histopathological analysis of GVHD target organs from
CEACAM-1-/- recipients of WT T cells revealed signiﬁcantly
increased GVHD of the large bowel (p0.05) and the thymus
(p0.05) as compared with WT controls.
Additionally, alloreactive splenic CD8 CEACAM-1-/- T cells
from recipients with GVHD had increased levels of 
47 integrin
(LPAM) as compared to WT controls. We also found increased
numbers of intraepithelial lymphocytes and mesenteric lymph
node cellularity in CEACAM-1-/- recipients of WT T cells.
Furthermore, adoptive transfer of CFSE-labeled CEACAM-1-/-
T cells into WT hosts, or of WT T cells into CEACAM-1-/- hosts
revealed more profound activation of T cells in the CEACAM-1
deﬁcient setting as demonstrated by increased early CD25 expres-
sion and CD62L downregulation on fast-cycling alloreactive T
cells in the spleen and liver.
We found no signiﬁcant differences in serum levels of TNF-
 or
interferon-, T cell proliferation kinetics upon adoptive transfer,
percentages of alloactivated CD4 and CD8 cells, or percentages of
CD4FoxP3 regulatory T cells in WT recipients of CEACAM-
1-/- T cells, CEACAM-1-/- recipients of WT T cells, and WT
recipients of WT T cells.
We conclude that CEACAM-1 deﬁciency on donor T cells or in
recipients results in increased gut and systemic GVHD due to
increased T cell activation and expression of the gut homing
integrin 
47. This suggests that the use of CEACAM-1 agonists
could be a novel theraputic strategy for ameliorating acute intes-
tinal and systemic graft-versus-host-disease. Studies with an ago-
nistic CEACAM-1 antibody are currently under way.
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GLOBAL ASSESSMENT OF B CELL ALLOIMMUNITY USING MICROAR-
RAYS OF 5000 HUMAN PROTEINS
Wadia, P.P.1, Coram, M.1, Weintraub, L.1, Butte, A.1, Miklos, D.1
1Stanford University School of Medicine, Stanford, CA.
Allogeneic Hematopoietic Cell Transplantation (HCT) can cure
hematologic malignancies through beneﬁcial graft-v-leukemia (GVL)
allo-immune responses, but is limited by graft-versus-host disease
(GVHD). Recent studies demonstrate allogeneic antibodies (Ab) de-
velop against minor histocompatibility antigens (mHA) encoded on
the Y-chromosome (H-Y antigens) develop after sex-mismatch HCT
in association with chronic GVHD and persistent disease remission.
We hypothesize that novel mHA can be serologically identiﬁed as
targets of allo-Ab responses that develop post-transplant but are ab-
sent pre-transplant. ProtoArray™ (Invitrogen) displays 5,000 full-
length human proteins with N-terminal GST epitopes expressed in
baculovirus and afﬁnity puriﬁed under native conditions maintaining
their cellular enzymatic activities/native conformations. Technical
replicates of 8 plasma measured at 1:50, 1:150, 1:500 provided corre-
lation coefﬁents, R20.94-0.97 conﬁrming technical feasibility. In
order to identify targets of allo-Ab, pretransplant ﬂuorescent signal
intensities were subtracted from their one-year plasma results for all
5000 antigens. While Ab responses were unchanged for 4600 (92%)
antigens, new allo-Ab responses targeted 60-75 antigens with ﬂuores-
cent differences ranging 0.5 to 3 logs. In comparison with their
respective donor results, 30-40% appear to result from adoptive do-
nor transfer while the remaining develop de novo . Over 90% of
allo-Ab targets have known non-synonymous SNP which when dis-
parate in donor and recipient may elicit alloimmunity and this geno-
typing is ongoing. No single protein was recognized by “new” Ab
responses in all patients, however polymorphic proteins Growth Ar-
rest Speciﬁc-7 (GAS7), laminin A/C, and ribosomal protein S19
(RPS19) were recognized by two of the four patients after HCT.
Results from plasma samples collected 3, 6, 9 and 12 months after
HCT demonstrate the progression of alloimmune immune responses.
Though these novel mHA require validation by large clinically char-
acterized patient samples, protein microarrays are innovative, power-
ful tools for high-throughput global assessment of B -cell alloimmu-
nity after HCT providing sufﬁcient reproducibility for candidate
mHA discovery.
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EFFECTIVE GRAFT-VERSUS-LEUKEMIA RESPONSES ARE ASSOCIATED
WITH THE PRESENCE OF NUCLEIC ACID-IMMUNOGLOBULIN COM-
PLEXES THAT STIMULATE TOLL-LIKE RECEPTORS (TLR) 8 AND 9
Lin, Y.1, Means, T.4, Alyea, E.P.1,2,3, Canning, C.M.1,
Soiffer, R.J.1,2,3, Ritz, J.1,2,3, Wu, C.J.1,2,3 1Dana-Farber Cancer
Institute, Boston, MA; 2Department of Medicine, Brigham and Wom-
en’s Hospital, Boston, MA; 3Harvard Medical School, Boston, MA;
4Division of Rheumatology, Allergy and Immunology, Massaschusetts
General Hospital, Charlestown, MA.
In patients with chronic myeloid leukemia (CML) who demon-
strated effective graft-versus-leukemia (GvL) responses after DLI
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